Adverum Biotechnologies’ (ADVM) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Adverum Biotechnologies (NASDAQ:ADVM) in a report released on Monday, MarketBeat reports. The firm currently has a $5.00 price objective on the biotechnology company’s stock, down from their previous price objective of $30.00. HC Wainwright also issued estimates for Adverum Biotechnologies’ Q4 2025 earnings at ($2.14) EPS, FY2025 earnings at ($8.73) EPS, Q1 2026 earnings at ($1.98) EPS, Q2 2026 earnings at ($2.00) EPS, Q3 2026 earnings at ($2.09) EPS, Q4 2026 earnings at ($2.16) EPS and FY2026 earnings at ($8.25) EPS.

Several other equities analysts have also issued reports on the stock. Chardan Capital lowered shares of Adverum Biotechnologies from a “strong-buy” rating to a “hold” rating in a report on Monday, October 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adverum Biotechnologies in a research note on Wednesday, October 8th. Truist Financial set a $5.00 target price on Adverum Biotechnologies in a report on Friday, October 24th. Mizuho set a $5.50 price target on Adverum Biotechnologies in a report on Wednesday, October 29th. Finally, Royal Bank Of Canada set a $4.00 price target on Adverum Biotechnologies in a research report on Tuesday, October 28th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $10.50.

Adverum Biotechnologies Price Performance

NASDAQ:ADVM opened at $4.25 on Monday. The firm’s 50-day moving average price is $4.26 and its 200-day moving average price is $3.20. The company has a market capitalization of $93.83 million, a PE ratio of -0.54 and a beta of 1.01. Adverum Biotechnologies has a 1-year low of $1.78 and a 1-year high of $6.98.

Adverum Biotechnologies (NASDAQ:ADVM) last issued its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.80) by ($0.23). Equities analysts anticipate that Adverum Biotechnologies will post -4.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ADVM. BML Capital Management LLC grew its holdings in shares of Adverum Biotechnologies by 11.5% in the second quarter. BML Capital Management LLC now owns 3,057,526 shares of the biotechnology company’s stock worth $6,574,000 after acquiring an additional 315,209 shares during the period. Pale Fire Capital SE raised its position in shares of Adverum Biotechnologies by 16.9% during the 1st quarter. Pale Fire Capital SE now owns 368,267 shares of the biotechnology company’s stock valued at $1,609,000 after purchasing an additional 53,113 shares during the period. Two Sigma Investments LP lifted its position in shares of Adverum Biotechnologies by 372.7% in the third quarter. Two Sigma Investments LP now owns 88,670 shares of the biotechnology company’s stock valued at $402,000 after acquiring an additional 69,913 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Adverum Biotechnologies in the second quarter worth about $153,000. Finally, Invesco Ltd. purchased a new stake in shares of Adverum Biotechnologies during the first quarter worth about $218,000. 48.17% of the stock is owned by hedge funds and other institutional investors.

About Adverum Biotechnologies

Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.